This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Nexstim Crecimiento futuro

Future controles de criterios 3/6

Información clave

30.9%

Tasa de crecimiento de los beneficios

42.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	24.5%
Tasa de crecimiento de los ingresos	9.6%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	01 Mar 2023

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

OM:NXTMS - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	12	2	N/A	N/A	1
12/31/2024	10	0	1	1	2
12/31/2023	8	-1	-1	-1	2
12/31/2022	11	1	0	1	N/A
9/30/2022	11	2	0	2	N/A
6/30/2022	12	3	0	2	N/A
3/31/2022	10	1	-2	0	N/A
12/31/2021	8	-1	-4	-2	N/A
9/30/2021	7	-2	-4	-3	N/A
6/30/2021	6	-4	-4	-3	N/A
3/31/2021	5	-4	-3	-3	N/A
12/31/2020	4	-4	-3	-3	N/A
9/30/2020	4	-4	-4	-4	N/A
6/30/2020	4	-4	-5	-5	N/A
3/31/2020	4	-6	-6	-6	N/A
12/31/2019	3	-7	-8	-7	N/A
9/30/2019	3	-7	-8	-7	N/A
6/30/2019	3	-7	-7	-7	N/A
3/31/2019	3	-7	-7	-6	N/A
12/31/2018	3	-6	-7	-6	N/A
9/30/2018	3	-6	-6	-6	N/A
6/30/2018	3	-6	-6	-6	N/A
3/31/2018	3	-7	-6	-6	N/A
12/31/2017	3	-7	-6	-5	N/A
9/30/2017	3	-7	-5	-5	N/A
6/30/2017	3	-6	-5	-5	N/A
3/31/2017	3	-6	-6	-6	N/A
12/31/2016	3	-7	-8	-7	N/A
9/30/2016	3	-8	N/A	-8	N/A
6/30/2016	3	-9	N/A	-10	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: NXTMS's forecast earnings growth (30.9% per year) is above the savings rate (0.5%).

Beneficios vs. Mercado: NXTMS's earnings (30.9% per year) are forecast to grow faster than the Swedish market (18.8% per year).

Beneficios de alto crecimiento: NXTMS's earnings are expected to grow significantly over the next 3 years.

Ingresos vs. Mercado: NXTMS's revenue (9.6% per year) is forecast to grow slower than the Swedish market (10% per year).

Ingresos de alto crecimiento: NXTMS's revenue (9.6% per year) is forecast to grow slower than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Insufficient data to determine if NXTMS's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Nexstim Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Nexstim Plc Provides Earnings Guidance for the Year 2022

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Recent updates

Nexstim Applies for Delisting Regarding the Secondary Listing of its Shares from Nasdaq First North Growth Market Sweden

Nexstim Plc, Annual General Meeting, Mar 31, 2023

Nexstim Reports Excellent Treatment Outcomes of over 400 MDD Patients in Patient Registry

Nexstim plc Appoints Tero Weckroth as A New Member of the Nomination Committee

First half 2022 earnings released

Nexstim Plc Provides Earnings Guidance for the Year 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Full year 2021 earnings: Revenues exceed analyst expectations

Nexstim Reaches Over 300 Completed Treatment Sessions – Continues to Report a Remission Rate Greater than 50% of MDD Patients in the Patient Registry

Nexstim Plc Announces Results of the Pilot Study in Chronic Pain Treatment At Helsinki University Hospital

Nexstim Plc Receives System Orders from Existing Hospital Customers in Finland

Nexstim Announces Continuation of Pilot Study in Treatment of Severe Depression at Kuopio University Hospital

First half 2021 earnings released: €0.17 loss per share (vs €1.25 loss in 1H 2020)

Nexstim Plc Provides Update on Pilot Study in Chronic Pain Treatment at Helsinki University Hospital

Nexstim Plc Continues to Report Very Promising MDD Treatment Outcomes with Remission Rate Greater Than 50%

Nexstim Plc Granted Authorization for Commercial Distribution of NBS System in Australia

Nexstim Gives an Update on its Promising Treatment Results of Major Depressive Disorder

Nexstim plc Receives Two NBS System Orders from Hospitals in Norway and the Us

Nexstim plc Provides Encouraging Results of the Initial Pilot Study in Severe Depression At Kuopio University Hospital

Full year 2020 earnings released

Revenue beats expectations

New 90-day high: kr1.02

German University Hospital Orders Nexstim NBS System with NexSpeech

Rohan Hoare and Tomas Holmberg No Longer Be Available to Nexstim Plc's Board of Directors for the Period 2021-2022

New 90-day high: kr1.01

Nexstim plc Receives Three New NBS System Orders

New 90-day high: kr0.69

Nexstim Plc Receives Two New NBT® System Purchase Orders in the United States

Nexstim plc Provides an Update on the Pilot Study in Severe Depression At Kuopio University Hospital

Nexstim Plc Receives an Order and Signs Purchase Agreement to Develop Two Prototype Systems Enabling Introduction of Novel Research Tool for Probing and Diagnosing the Brain

Nexstim plc Continues to Report Promising Results in Quickly Growing Number of Patients Completing SmartFocus rTMS Treatment of Major Depressive Disorder

New 90-day high: kr0.41

Pilot Study for New Depression Treatment Protocol with Nexstim NBT® System Starts in Kuopio University Hospital

New 90-day high - kr0.29

Earnings released

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento